2018
DOI: 10.1038/s41467-017-02261-1
|View full text |Cite
|
Sign up to set email alerts
|

Engineered nanointerfaces for microfluidic isolation and molecular profiling of tumor-specific extracellular vesicles

Abstract: Extracellular vesicles (EVs) carry RNA, DNA, proteins, and lipids. Specifically, tumor-derived EVs have the potential to be utilized as disease-specific biomarkers. However, a lack of methods to isolate tumor-specific EVs has limited their use in clinical settings. Here we report a sensitive analytical microfluidic platform (EVHB-Chip) that enables tumor-specific EV-RNA isolation within 3 h. Using the EVHB-Chip, we achieve 94% tumor-EV specificity, a limit of detection of 100 EVs per μL, and a 10-fold increase… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
247
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 274 publications
(249 citation statements)
references
References 59 publications
2
247
0
Order By: Relevance
“…22, 110113 In this approach, EVs are captured with specific antibodies against common EV markers including the tetraspanins ( e.g. , CD9, CD63, CD81) as well as tumor-associated markers ( e.g.…”
Section: Ev Enrichmentmentioning
confidence: 99%
“…22, 110113 In this approach, EVs are captured with specific antibodies against common EV markers including the tetraspanins ( e.g. , CD9, CD63, CD81) as well as tumor-associated markers ( e.g.…”
Section: Ev Enrichmentmentioning
confidence: 99%
“…Microfluidic chip is capable to effectively isolate exosomal ingredients as well. Reategui et al . established a microfluidic platform named (EV)HB‐Chip which captured glioblastoma multiforme‐derived characteristic exosomal RNA within 3 hr, contributing to identifying specific genes and subtypes of this disease.…”
Section: The Innovative Approaches To Detect Tumor‐derived Exosomes Fmentioning
confidence: 99%
“…Recent IV‐MPM studies have provided preliminary data on EV dynamics and EV effects (see Section ), but the full composition of EVs is unknown. A recent microfluidic platform designed to isolate tumor‐derived EVs from blood was used to provide patient‐derived EVs for next‐generation RNA sequencing, demonstrating the heterogeneity of glioblastomas . A similar approach may be used in the future to provide detailed functional analysis of tumor EVs imaged by IV‐MPM.…”
Section: Extending and Complementing The Capabilities Of Iv‐mpmmentioning
confidence: 99%